ProMetic would like to bring to your attention a recently published article titled "FDA Considers Restricting Amgen Anemia Drugs".
This article states that the Food and Drug Administration is considering new restrictions on widely used anemia drugs that appear to double the risk of stroke in patients with kidney disease and in addition the FDA review states that the ?Treatment did not eliminate the risk of requiring (red blood cell) transfusions".
Given that ProMetic?s PBI-1402 compound does not elevate hemoglobin or red blood cells to potentially dangerous levels (no overshoot), it provides unique positioning strategies for this medical condition that the Company is actively pursuing.
Die Faktenlage von Prometic hat sich seit Anfang September verändert: - neue Partnerschaft mit Allist - quartalsbericht ok, wieder einige verbesserungen - fda zieht restriktionen bezüglich anämie-medikamenten in betracht, die in konkurrenz zu PBI-1402 stehen = bessere bzw. super chancen für PBI-1402, weil andere funtionsweise! - nur der aktienkurs scheint davon noch nicht so richtig etwas mitbekommen zu haben...
wenn ab nächsten jahr die italiener ihre licensing fees an prometic abstottern, gibt es wahrscheinlich den ersten knall richtung decke (was natürlich auch wunschdenken widerspiegelt). dennoch gibt es sonst keine bad news, die den niedrigen kurs rechtfertigen. prometic stellt sich für die zukunft auf! vor einigen jahren war es sumitomo für japan, jetzt kommt allist für china hinzu; m.e. die kaufchance. und jetzt drücken wir mal hier schön die daumen...
Noch mal zu Erinnerung: Der Kurs in Deutschland sagt übrhaupt nichts aus (außer Berlin vielleicht). Guckt euch die 12 CAD-Cent an in Toronto!!! Da wird die Musik gemacht. Und ja, mea culpa, ich habe es immer noch nicht geschafft eine neue Prognose zu PLI zu machen. Aber ich arbeite dran ;-).... Und jetzt steig endlich an, du Sau! TheOracleX
du, ich bin gar nicht in town und hab echt zufällig mal reingeschaut freut mich dass du noch interesse an prometic hast werde hier demnächst was reinstellen aber dauert noch familie und job nimmt mich voll in Anspruch bis bald oracle
Dem kann und will ich eigentlich nichts mehr hinzufügen, da alles wichtige bereits gesagt wurde. Ich glaube weiterhin an Prometic und bescheinige ihr nach wie vor großes Potential. Good luck allen investierten und bis bald, TheOracleX
Vor dem Hintergrund der jüngsten Entwicklungen (siehe Posting oben von Oracle) gehe ich ab spätestens Ende 2011 von schwarzen Zahlen aus. Dass die Anteilseigner auf die Rückzahlung ihrer gesicherten Anleihen bis Juli 2012 verzichten, damit Prometic sich voll auf die Fortentwicklung ihrer Produkte konzentrieren kann, sehe ich wie in der Mitteilung verfasst als Vertrauen in die Firma. Gleichzeitig wird durch die Verschiebung der Einfluss (gemessen an den Anteilen) von Allist Pharmac. begrenzt. Zur Erinnerung: Ausserdem werden dieses Jahr soweit ich weiß erste Lizenzzahlungen von Kedrion für Mimetic-Ligand-Produkte fällig, überdies noch andere Milestone-Payments. Aber der Knüller ist folgende Geschichte: Dieses Jahr wird von der britischen Regierung endgültig ein Urteil erwartet, ob landesweit Prionenfilter bei Blutentnahmen bzw. Bluttransfusionen verwendet werden müssen. Irland und Macao haben bekanntlich damit angefangen, sollte GB nachziehen wird in Zukunft die Welle auch auf das Festland schwappen. Gerade Erkrankungen wie Creutzfeld-Jakob oder Alzheimer können dadurch ziemlich wirksam eingedämmt werden.
Hoffen wir also das Beste für unsere kleine feine Perle!
Kann mir einer mal erklären, warum Prometic nicht an der TMX gehandelt wird? Scheint jedenfalls kein Feiertag zu sein, da andere Werte munter über den Tisch gehen. Danke im voraus für eure Antworten. Oki-Wan 2.0
Dein letztes posting trifft den Nagel auf den Kopf. 2011 wird allem Anschein nach ein bombiges Jahr für Prometic. Ich hoffe nur dass die Securities holder nicht auf ihr Geld verzichten, weil sonst Prometic pleite ist. OracleX
folgende Nachricht wurde heute von Prometic herausgegeben und sollte manchem als Anregung dienen, sich mehr über Prometic zu informieren. Mir schwant da was...
ProMetic achieves pivotal milestone for its plasma-derived therapeutics business
Company secures an established state-of-the-art manufacturing facility on very favourable terms
Facility to scale-up ProMetic's proven manufacturing technology for plasma-derived therapeutics ("PPPSTM") with a targeted capacity of 150,000 liters of plasma annually
New subsidiary "NewCo" created to undertake product manufacturing with targeted start-up by the end of 2011
NewCo to be funded by third party investors, stakeholders and government grants
Initial equity investment of $2.5 M CDN in NewCo has been committed; of which a first tranche of $750,000 CDN has been received
MONTREAL, QUEBEC, CANADA - February 7, 2011 - ProMetic Life Sciences Inc. (TSX:PLI) ("ProMetic") announced today that the Company has achieved a pivotal milestone for the in-house manufacturing of plasma-derived proteins at commercial scale thereby expanding its reach into the lucrative plasma-derived therapeutics industry.
ProMetic, via its new subsidiary, NewCo, has entered into a long-term lease on very favorable conditions with Quebec's Institut national de la recherche scientifique ("INRS") for an existing state-of-the-art facility.
NewCo will undertake the development and manufacturing of high-value plasma-derived therapeutic biosimilars for ProMetic's current and future clients. This facility, located in Laval's biotech cluster, will have a targeted processing capacity of 150,000 liters which would supply products with a market value exceeding $100,000,000 CDN per annum.
NewCo will be funded via third-party investments and is anticipated NewCo will rapidly become self-sustaining through end product services and sales to ProMetic's existing clients. An initial $750,000 CDN investment has been received as part of a $2,500,000 CDN commitment.
This new business venture has also received pledges for additional funding from various institutions and key stakeholders involved in ProMetic's protein technologies activities which could amount to additional financial contributions of $3,500,000 CDN.
"This is a key development for ProMetic as it enables the Company to benefit, at commercial scale, from the competitive advantage provided by our proven Plasma Protein Purification System ("PPPSTM") as well as our prion capture technologies. Our clients will have access to ProMetic's in-house production of plasma-derived products, in addition to technology transfer and skills training services," said Mr. Pierre Laurin, ProMetic's President and Chief Executive Officer.
Mr. Bruce Pritchard, ProMetic's Chief Financial Officer stated: "We are very pleased to have accessed such a high quality facility on such very favorable terms, as well as having attracted capital to catalyze this exciting venture. The manufacturing plant will supply plasma-derived therapeutic products to our existing and future clients which should generate significant revenue". Mr. Pritchard added: "The plant is expected to start up operations by the end of 2011, provide cGMP products to be used by clients in early 2012, and reach full operating capacity by 2014".
ProMetic will further reduce its overhead cost by relocating its headquarters at this new facility, at the end of March, 2011. This also allows ProMetic to concentrate its core activities near its existing Therapeutic division's research and development site.
ProMetic will be holding a conference call / webcast on Tuesday, February 8, 2011, at 14:00 (EDT) to discuss details regarding this announcement.
The numbers to access the conference call are (416) 981-9000 (international) and 1 (800) 925-4216 (North America toll free). A live audio webcast of the conference call will be available through ProMetic's website at http://www.prometic.com/en/news-events/events.php.
An audio replay of the call will be available for a period of seven days as of Tuesday, February 8, 2011, at 17:00 (EDT). The numbers to access the audio replay are (416) 626-4100 and 1 (800) 558-5253 using access code 21510428. The replay of the web cast may be downloaded directly from ProMetic's web site.
About the Plasma Protein Purification System The Plasma Protein Purification System ("PPPSTM") allows for the targeting and removal of multiple high-value proteins from a single plasma sample at unprecedented activity levels using ProMetic's Mimetic LigandTM adsorbent technology. This system also provides for the recovery of new biotherapeutics as they are discovered and identified. The effect of this process is to reduce the significant losses incurred when using the more conventional Cohn precipitation process
About ProMetic Life Sciences Inc. ProMetic Life Sciences Inc. (http://www.prometic.com/) is a biopharmaceutical company specialized in the research, development, manufacture and marketing of a variety of commercial applications derived from its proprietary Mimetic LigandTM technology. This technology is used in large-scale purification of biologics and the elimination of pathogens. ProMetic is also active in therapeutic drug development with the mission to bring to market effective, innovative, lower cost, less toxic products for the treatment of hematology and cancer. Its drug discovery platform is focused on replacing complex, expensive proteins with synthetic "drug-like" protein mimetics. Headquartered in Montréal (Canada), ProMetic has R&D facilities in the UK, the U.S. and Canada, manufacturing facilities in the UK and business development activities in the U.S., Europe, Asia and in the Middle-East.
Forward Looking Statements This press release contains forward-looking statements about ProMetic's objectives, strategies and businesses that involve risks and uncertainties. These statements are "forward-looking" because they are based on our current expectations about the markets we operate in and on various estimates and assumptions. Actual events or results may differ materially from those anticipated in these forward-looking statements if known or unknown risks affect our business, or if our estimates or assumptions turn out to be inaccurate. Such risks and assumptions include, but are not limited to, ProMetic's ability to develop, manufacture, and successfully commercialize value-added pharmaceutical products, the availability of funds and resources to pursue R&D projects, the successful and timely completion of clinical studies, the ability of ProMetic to take advantage of business opportunities in the pharmaceutical industry, uncertainties related to the regulatory process and general changes in economic conditions. You will find a more detailed assessment of the risks that could cause actual events or results to materially differ from our current expectations on page 24 of ProMetic's Annual Information Form for the year ended December 31, 2009, under the heading "Risk Factors". As a result, we cannot guarantee that any forward-looking statement will materialize. We assume no obligation to update any forward-looking statement even if new information becomes available, as a result of future events or for any other reason, unless required by applicable securities laws and regulations. All amounts are in Canadian dollars unless stated otherwise.
: Und wieder neue Sachen von PLI bzw. der Tochter...
Also mir scheint immer mehr, dass ein technischer Angriff im Gange ist. Wie sagt man so schön in der Fachsprache: mit einer bestimmten Strategie einen bestimmten Markt penetrieren.
Jedenfalls ähnelt das Erscheinungsbild immer mehr dem eines zukünftigen multinationalen Konzerns. Dazu sei angemerkt, dass Prometic Biosciences eine 100%ige Tochter von PLI ist und deren Produkte in Europa verkauft und demnächst auch in Asien anbieten will (Macao läuft schon).
Allen Investierten ein Toi Toi Toi und Daumen hoch...
Welcome to the BioPurification Quarterly™.We designed this newsletter for our customers in order to keep you informed on the latest developments within ProMetic BioSciences Ltd (PBL) and the industry we serve.
Inside this issue of BioPurification Quarterly™ we explain how PBL can custom design an affinity chromatography adsorbent to suit your bio-processing needs and describe the application of in silico techniques to develop novel ligands for affinity chromatography. We would also like to welcome our new EMEA and Asian Sales Manager - Mr. Steve Profit.
Dr. Dev continues to offer his technical insight by discussing the differences between PBL's proprietary base matrices - PuraBead® 6XL and PuraBead® 6HF and we provide an overview of upcoming events for 2011.
Thanks again for your support and we hope you enjoy this edition of the newsletter.
Custom Designed Affinity Chromatography Adsorbents
Our on-line shop has a number of off-the-shelf products to help in numerous bio-processing applications. This enables you to choose the best option quickly and place orders securely online.
However, if you have a specific requirement for a bioseparation adsorbent not listed in our on-line catalogue PBL's technical team can help you identify a product which meets your specific process performance specifications. PBL has over 20 years experience in either optimizing existing products or designing a new custom adsorbent/resin specifically for your specific target protein.
Our in-house scientific and technical teams are world leading experts in the development and synthesis of affinity chromatography adsorbents and resins. Our processes are fully scalable and can meet all challenges, taking small scale adsorbents/resins (<25 mL) up to fully validated, regulated and supported products (>250 L). Our products are manufactured to an ISO 9001 accredited standard.
Below illustrates some of the different options available:
Numerous adsorbent base matrices (e.g. PuraBead® 6XL, PuraBead® 6HF) for ligand attachment.
Adsorbent slurry available for packing in either axial or radial flow columns.
Pre-packed chromatography columns or single-use column applications.
Optimisation of any of our current off-the-shelf products for general and specific bio-processing needs (e.g. varying adsorbent base matrix, ligand density, spacer arm chemistry).
A variety of custom ligand discovery programs are available from ~4 weeks (QuickScreen) to ~17 weeks (Full Discovery Project - Stage 1) for lead candidate identification, varying in complexity depending on your target protein requirements.
A full downstream processing development package to help optimise your purification needs.
So please feel free to contact us via email@example.com if you have any requests regarding adsorbents or resins not mentioned in our on-line shop or if you have a requirement for something slightly different based on our current products.
Application of in silico techniques to develop novels ligands for affinity chromatography
Early stage application of affinity chromatography in downstream processing is acknowledged as a desirable objective with the potential to increase yields and reduce the overall cost of goods. While protein engineering technologies are producing increasingly diverse therapeutic proteins - whole molecules, fragments, fusion proteins - advances in bioprocess development are enabling their production at industrial scale. Concomitant with these developments is an increase in the demand for sufficiently robust synthetic affinity ligands with appropriate protein binding selectivites as primary capture affinity adsorbents.
In the absence of suitable existing ligands, the development of completely new ligands has analogies with the development of novel drug compounds and the computational techniques used in the search for novel drug compounds have been adapted and used by ProMetic to inform a number of stages in the affinity ligand design process, and to gain an understanding of both the target protein and adsorbent interactions.
PBL has extensive knowledge of in silico modeling techniques, successfully applying its bioinformatics modeling suite to identify lead candidate adsorbents in a variety of projects. PBL provides customers with a range of services, from virtual screening, to the application of in silico techniques within a custom ligand discovery program:
Screening of virtual ligand libraries.
Diverse or focused ligand selection from virtual 'chemical space' (Chemical Combinatorial Library CCL® ~100,000 triazine based ligands).
Evaluating potential binding sites using structural/functional importance and blind docking 'roaming' of ligands to target protein (using crystallographic information).
Screening designed combinatorial libraries to further explore surrounding chemical space of lead screening hits.
Investigating the effects of support, spacer arm and surface chemistry on binding interactions by molecular dynamic modeling.
Mr. Steve Profit has recently joined ProMetic as the EMEA and Asian sales & marketing manager. Steve has over 20 years experience in sales and marketing having previously worked in senior European and global positions for Sigma Aldrich and Millipore. Mr. Profit holds a M.Sc. Biomolecular Technology and a B.Sc. in Applied Biology.
If you would like to contact Steve with regards to any of our products or services please use the details below:
Dear Dev- Can you please provide me information on the base matrix used for ProMetic BioSciences Ltd chromatography adsorbents. What is the difference between PuraBead® 6XL and PuraBead® 6HF?
Answer- PuraBead® is a 6% agarose bead manufactured by a novel method which does not use any organic solvents in the beading process. This provides uniform near mono-disperse beads with mean bead diameter from 90 to 100 microns.
After beading the matrix is cross-linked to provide material for derivatisation with affinity ligands.
Two different types of cross-linking chemistry are used; one to provide PuraBead® 6XL, and one to provide PuraBead® 6HF. The key difference between the cross-linking chemistries is the much higher flow rate provided by the HF cross-linking chemistry. The XL cross-linking chemistry provides very low non-specific binding and enables higher ligand densities.
Both types of PuraBead® are used to make Mimetic Blue® SA HL adsorbents including the standard Mimetic Blue® SA HL P6XL product which is widely used for purification of albumin and albumin-fusion proteins and the new Mimetic Blue® SA HL P6HF which provides the same selectivity and capacity with exceptional flow properties.
The properties of the two cross-linked base matrices are summarized below:
IBC Biopharmaceutical Development & Production Week Date: March 14, 2011 Location: Hyatt Regency Bellevue, WA For more information or to register click here Save 25% off this conference compliments of PBL! Use Priority Code: BDPSPX29 when registering to receive your discount
PRION 2011: New World Date: May 16-19, 2011 Location: Fairmont Queen Elizabeth Hotel Montreal, Quebec For more information click here
BioProcess International Europe Conference and Exhibition Date: April 6-7, 2011 Location: Nice Acropolis Des Congres, France For more information click here
ProMetic BioSciences Ltd is a private company limited by shares, incorporated in the Isle of Man with registered number 034251C. The company is also registered as a foreign company at Companies House in the UK, with registration number FC027128. ProMetic BioSciences UK is the branch name of ProMetic BioSciences Ltd, and is registered as a Branch in England & Wales with registration number BR009067. The registered office of ProMetic BioSciences UK and ProMetic BioSciences Ltd is Freeport, Ballasalla, Isle of Man, IM9 2AP, British Isles. The liability of the members of ProMetic BioSciences Ltd is limited.
Ich befürchte, weil die Aktie hier weitgehend unbekannt ist. Übrigens werde ich gleich einen neuen Thread zu Prometic eröffnen. Ich finde, der alte Name "... - die bessere Genta" ist nun wirklich irreführend!